Home » SPEEDEL STARTS PHASE I TESTING OF SPP635 IN HEALTHY VOLUNTEERS
SPEEDEL STARTS PHASE I TESTING OF SPP635 IN HEALTHY VOLUNTEERS
Speedel has announced the start of its Phase I safety and tolerability testing of SPP635, one of a new series of renin inhibitors for the treatment of hypertension and for protecting organs such as the heart, kidneys and blood vessels. The Phase I trial, which tests the safety and tolerability of single and multiple oral doses in healthy volunteers, is expected to finish in the second half of 2006.
The trial is a randomized, placebo-controlled study, designed to assess the pharmacokinetics, inhibition of the renin-angiotensin system, clinical safety and tolerability of rising single and multiple oral doses of SPP635.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May